Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP

Patients with carcinoma of unknown primary (CUP) have a dismal prognosis, even when treated with multi-agent chemotherapy. We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to standard first-line chemotherapy with paclitaxel and carboplatin would improve PFS...

Full description

Bibliographic Details

Main Authors:	Folprecht, Gunnar (Author) , Trautmann, Karolin (Author) , Stein, Alexander (Author) , Huebner, Gerdt (Author) , Stahl, Michael (Author) , Kasper, Stefan (Author) , Kretzschmar, Albrecht (Author) , Köhne, Claus-Henning (Author) , Grünwald, Viktor (Author) , Hofheinz, Ralf-Dieter (Author) , Schütte, Katharina (Author) , Löffler, Harald (Author) , Bokemeyer, Carsten (Author) , Krämer, Alwin (Author)
Format:	Article (Journal)
Language:	English
Published:	2021
In:	British journal of cancer Year: 2021, Volume: 124, Issue: 4, Pages: 721-727
ISSN:	1532-1827
DOI:	10.1038/s41416-020-01141-8
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41416-020-01141-8 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41416-020-01141-8
Author Notes:	Gunnar Folprecht, Karolin Trautmann, Alexander Stein, Gerdt Huebner, Michael Stahl, Stefan Kasper, Albrecht Kretzschmar, Claus-Henning Köhne, Viktor Grünwald, Ralf-Dieter Hofheinz, Katharina Schütte, Harald Löffler, Carsten Bokemeyer, Alwin Krämer and Arbeitsgemeinschaft Internistische Onkologie (AIO) - CUP Group